We have located links that may give you full text access.
Iodinated contrast prior to evaluation for thyrotoxicosis.
BACKGROUND: Radioactive iodine is useful in the diagnosis and treatment of patients with newly diagnosed thyrotoxicosis. However, in many patients these tests are not possible to obtain due to recent administration of iodinated contrast for other types of diagnostic studies, most frequently computed tomography (CT) scans.
OBJECTIVE: To determine the frequency of iodinated contrast use in hospital inpatients newly diagnosed with thyrotoxicosis and the utility of these studies.
DESIGN: Retrospective chart review.
SETTING: Academic medical center.
INTERVENTION: None.
PATIENTS: Inpatients with newly diagnosed thyrotoxicosis who were seen in consultation by the endocrinology service.
MEASUREMENTS: The records of inpatient endocrinology consultations (n = 1171) performed by our service over a 4-year period were reviewed. Records of patients with newly diagnosed thyrotoxicosis were identified and reviewed to determine if iodinated contrast had been recently administered, the types of studies it was used for, and the results of those studies.
RESULTS: Forty-five patients (45%) had been given iodinated contrast within 2 weeks prior to endocrinology evaluation, 43 for CT scanning, and 2 for angiography. Of the patients who underwent CT scanning, 7 (16%) had a finding that potentially changed their inpatient management. Only 1 of these patients required emergent treatment of a condition diagnosed by CT scan before further diagnostic studies could have been performed.
CONCLUSIONS: A substantial number of inpatients with thyrotoxicosis receive iodinated contrast prior to endocrinologic evaluation. Acute findings from these studies that change patient management are uncommon. Awareness of this issue may facilitate care of hospitalized patients with thyrotoxicosis.
OBJECTIVE: To determine the frequency of iodinated contrast use in hospital inpatients newly diagnosed with thyrotoxicosis and the utility of these studies.
DESIGN: Retrospective chart review.
SETTING: Academic medical center.
INTERVENTION: None.
PATIENTS: Inpatients with newly diagnosed thyrotoxicosis who were seen in consultation by the endocrinology service.
MEASUREMENTS: The records of inpatient endocrinology consultations (n = 1171) performed by our service over a 4-year period were reviewed. Records of patients with newly diagnosed thyrotoxicosis were identified and reviewed to determine if iodinated contrast had been recently administered, the types of studies it was used for, and the results of those studies.
RESULTS: Forty-five patients (45%) had been given iodinated contrast within 2 weeks prior to endocrinology evaluation, 43 for CT scanning, and 2 for angiography. Of the patients who underwent CT scanning, 7 (16%) had a finding that potentially changed their inpatient management. Only 1 of these patients required emergent treatment of a condition diagnosed by CT scan before further diagnostic studies could have been performed.
CONCLUSIONS: A substantial number of inpatients with thyrotoxicosis receive iodinated contrast prior to endocrinologic evaluation. Acute findings from these studies that change patient management are uncommon. Awareness of this issue may facilitate care of hospitalized patients with thyrotoxicosis.
Full text links
Related Resources
Trending Papers
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.Endocrine Reviews 2024 April 28
The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association.Circulation 2024 April 26
British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults.Gut 2024 April 17
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Ventilator Waveforms May Give Clues to Expiratory Muscle Activity.American Journal of Respiratory and Critical Care Medicine 2024 April 25
Systemic lupus erythematosus.Lancet 2024 April 18
Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use.Pharmaceuticals 2024 March 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app